A detailed history of Creative Planning transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Creative Planning holds 3,299 shares of MDGL stock, worth $1.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,299
Previous 3,212 2.71%
Holding current value
$1.12 Million
Previous $899,000 22.14%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$212.22 - $292.96 $18,463 - $25,487
87 Added 2.71%
3,299 $700,000
Q2 2024

Aug 15, 2024

BUY
$193.33 - $291.99 $180,763 - $273,010
935 Added 41.06%
3,212 $899,000
Q1 2024

May 10, 2024

BUY
$171.37 - $283.23 $71,804 - $118,673
419 Added 22.55%
2,277 $608,000
Q4 2023

Feb 14, 2024

SELL
$120.4 - $237.13 $26,006 - $51,220
-216 Reduced 10.41%
1,858 $429,000
Q3 2023

Nov 16, 2023

BUY
$146.04 - $225.78 $302,886 - $468,267
2,074 New
2,074 $302,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.8B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.